<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunol Res</journal-id><journal-id journal-id-type="iso-abbrev">J Immunol Res</journal-id><journal-id journal-id-type="publisher-id">JIR</journal-id><journal-title-group><journal-title>Journal of Immunology Research</journal-title></journal-title-group><issn pub-type="ppub">2314-8861</issn><issn pub-type="epub">2314-7156</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6313977</article-id><article-id pub-id-type="doi">10.1155/2018/4325874</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Ren-You</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1681-0959</contrib-id><name><surname>Chung</surname><given-names>Wen-Hung</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chu</surname><given-names>Mu-Tzu</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Shu-Jen</given-names></name><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hua-Chien</given-names></name><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4163-2541</contrib-id><name><surname>Zheng</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="I8">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6531-5538</contrib-id><name><surname>Hung</surname><given-names>Shuen-Iu</given-names></name><email>sihung@ym.edu.tw</email><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei and Keelung, Taiwan</aff><aff id="I2">
<sup>2</sup>Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, Taiwan</aff><aff id="I3">
<sup>3</sup>College of Medicine, Chang Gung University, Taoyuan, Taiwan</aff><aff id="I4">
<sup>4</sup>Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan</aff><aff id="I5">
<sup>5</sup>Department of Dermatology, Xiamen Chang Gung Hospital, China</aff><aff id="I6">
<sup>6</sup>Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan</aff><aff id="I7">
<sup>7</sup>ACT Genomics, Taipei, Taiwan</aff><aff id="I8">
<sup>8</sup>The Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff><author-notes><fn fn-type="other"><p>Guest Editor: Lei Zhao</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>19</day><month>12</month><year>2018</year></pub-date><volume>2018</volume><elocation-id>4325874</elocation-id><history><date date-type="received"><day>12</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Ren-You Pan et al.</copyright-statement><copyright-year>2018</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Recently, increasing data show that immunotherapy could be a powerful weapon against cancers. Comparing to the traditional surgery, chemotherapy or radiotherapy, immunotherapy more specifically targets cancer cells, giving rise to the opportunities to the patients to have higher response rates and better quality of life and even to cure the disease. Cancer vaccines could be designed to target tumor-associated antigens (TAAs), cancer germline antigens, virus-associated antigens, or tumor-specific antigens (TSAs), which are also called neoantigens. The cancer vaccines could be cell-based (e.g., dendritic cell vaccine provenge (sipuleucel-T) targeting prostatic acid phosphatase for metastatic prostate cancer), peptide/protein-based, or gene- (DNA/RNA) based, with the different kinds of adjuvants. Neoantigens are tumor-specific and could be presented by MHC molecules and recognized by T lymphocytes, serving the ideal immune targets to increase the therapeutic specificity and decrease the risk of nonspecific autoimmunity. By targeting the shared antigens and private epitopes, the cancer vaccine has potential to treat the disease. Accordingly, personalized neoantigen-based immunotherapies are emerging. In this article, we review the literature and evidence of the advantage and application of cancer vaccine. We summarize the recent clinical trials of neoantigen cancer vaccines which were designed according to the patients' personal mutanome. With the rapid development of personalized immunotherapy, it is believed that tumors could be efficiently controlled and become curable in the new era of precision medicine.</p></abstract><funding-group><award-group><funding-source>National Science Council</funding-source><award-id>MOST105-2628-B-010-007-MY3</award-id><award-id>MOST104-2320-B-010-036-MY3</award-id><award-id>MOST104-2325-B-182A-006</award-id><award-id>MOST104-2314-B-182A-148-MY3</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Cancer cells have characteristics of genetic instabilities and accumulate somatic mutations rapidly (1&#x02013;4). The genome sequencing of cancer cells revealed heterogeneity, and tens to hundreds to thousands of somatic mutations amassed in individual patients. The high intertumoral heterogeneity is evidenced by The Cancer Genome Atlas (TCGA) database, which stores the genomic data of thousands of tumor specimens [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>]. There are various types of mutations, such as point mutations, insertion/deletions, gene amplification, and translocations in cancer cells. Some of them may lead to nonsynonymous somatic mutations altering the amino acid coding sequences and creating uncontrollable and abnormal proteins to promote cell proliferation. These aberrant peptide sequences could be seen by our immune system. Tumor-specific antigens (TSAs), called as neoantigens, are created by the genomic codon alternations, editing, usage, antigen processing, and presentation [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. Neoantigens could be presented by the major histocompatibility complex (MHC; also known as human leukocyte antigen (HLA) in humans) on the cell surface and recognized by the T lymphocytes. As neoantigens are tumor-specific and not expressed by normal cells [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>], they are ideal therapeutic targets and have great potential to maximize the therapeutic specificity, overcome the immune tolerance, and minimize the risk of autoimmunity. In this article, we review the literature of tumor antigens and cancer vaccines and also discuss the applications and values of this approach towards precision medicine.</p></sec><sec id="sec2"><title>2. Emerging Immunotherapies for Cancer Treatments</title><p>In recent years, immunotherapies rapidly develop and open a new era of cancer treatment. In 2011, the FDA first approved an immune checkpoint inhibitor (ICI), ipilimumab, a CTLA-4 blockage, which prolonged the overall survival rate of patients with metastatic melanoma [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Following this line, there are increasing ICI, such as anti-PD1 and anti-PD-L1 antibodies, proven to be effective and durable therapies in subsets of patients with a variety of tumor types: metastatic melanoma, nonsmall cell lung cancer (NSCLC), prostate cancer, renal cell carcinoma, and so on [<xref rid="B8" ref-type="bibr">8</xref>]. The response rates of ICI, however, are correlated with the mutation load of tumors of individuals and the presence of microsatellite instability (MSI) or DNA repair enzyme deficiency [<xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>]. Nevertheless, the use of ICI carries a risk to develop irAE (immune-related adverse events), which occur via nonspecific activation of the patient's immune system, leading to serious and even fatal adverse reactions [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. More efforts are needed to improve the response rates and tumor antigen specificity of ICI and to decrease the incidence of irAE. More recently, the first chimeric antigen receptor- (CAR-) T cell immunotherapy, anti-CD19 CAR-T for B cell lymphoma, was approved by the FDA in Aug 2017 [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. After that, there are increasing clinical trials using CAR-T therapy to treat cancers [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>]. CAR-T cells target the tumor-associated antigens (TAAs), such as CD19 on B cell malignancies [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>] and ERBB2 on breast cancers [<xref rid="B20" ref-type="bibr">20</xref>], which are also expressed on the normal cells. CAR-T therapy has the on-target but off-tumor side effect. Although CAR-T therapies have shown considerable promise in some acute lymphoid leukemia [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>], it is still a big challenge to treat solid cancers with CAR-T cells due to the lack of suitable TAAs. The reported overall objective response rates (ORR) of CAR-T therapy for solid tumors are still low [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>].</p><p>Targeting tumor-specific antigens (TSAs) has been considered an important therapeutic approach. As TSAs are exempt from central tolerance [<xref rid="B23" ref-type="bibr">23</xref>], these neoantigens could be presented by HLA and recognized by T lymphocytes of the immune system. Effective antitumor immunity in humans has been associated with the presence of T cells recognizing cancer neoantigens. The studies of adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes (TILs) revealed that neoantigen-specific T cells are crucial for clinical responses [<xref rid="B24" ref-type="bibr">24</xref>&#x02013;<xref rid="B27" ref-type="bibr">27</xref>]. The isolated T cell clones or T cell receptor- (TCR-) engineered T lymphocytes demonstrated the epitope patterns of neoantigens recognized by T cells [<xref rid="B28" ref-type="bibr">28</xref>&#x02013;<xref rid="B30" ref-type="bibr">30</xref>]. There are increasing neoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient's tumor [<xref rid="B31" ref-type="bibr">31</xref>]. Recently, two groups showed glimmers of the success of personalized cancer vaccines [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. Both the personalized RNA mutanome vaccines and peptide-based vaccines induced poly-specific therapeutic immunity against cancer [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. These neoantigen cancer vaccines demonstrated to be relatively safe, feasible, and capable of eliciting strong T cell responses to neoepitopes in patients with melanoma [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. Treatments tailored to a person's individual cancer mutations cause the strong immune response to attack tumors.</p></sec><sec id="sec3"><title>3. Tumor Antigens for Immunotherapy</title><p>Regarding the targets of immunotherapy, there are different types of tumor antigens, including tumor-associated antigens (TAAs), cancer germline antigens (CGAs), virus-associated antigens, and tumor-specific antigens (TSAs) (<xref rid="tab1" ref-type="table">Table 1</xref>).</p><p>Tumor-associated antigens (TAAs) are present in normal cells with low levels of expression but overexpressed on tumor cells in different patients. There are different kinds of TAAs, e.g., carcinoembryonic antigen (CEA) for GI cancer and PAP for prostate cancer. Using the universal antigens, various cancer vaccines have been designed for patients with tumor expressing the specific TAA. For example, stimuvax (BLP25 liposome vaccine) targeting MUC1 for NSCLC is in the phase III trial [<xref rid="B34" ref-type="bibr">34</xref>].</p><p>However, most attempts targeting TAAs in the cancer vaccination have met with limited success, as TAAs are normal host proteins and therefore subject to both central and peripheral tolerance mechanisms [<xref rid="B35" ref-type="bibr">35</xref>]. Due to the positive and negative selection, the high-affinity TCRs for TAAs are preferentially depleted, and the affinities of the remaining TCRs for TAAs are lower than that of the TCRs for foreign antigens [<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>]. In addition, targeting TAAs may cause autoimmune toxicities, such as colitis, severe hepatitis, renal impairment, rapid respiratory failure, and even death [<xref rid="B38" ref-type="bibr">38</xref>]. For example, targeting &#x0201c;carbonic anhydrase 9&#x0201d; caused severe liver toxicity, as this TAA is expressed in bile duct epithelial cells. Nevertheless, using TAAs as immunotherapy targets still has its clinical value. CAR-T therapy targeting CD19 in patients with acute lymphoblastic leukemia (ALL) showed complete remission in high proportion of patients, though life-long administration of IVIG is needed for the patients [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>].</p><p>Cancer germline antigens (CGAs), also called cancer/testis antigens (CTAs), are present in reproductive tissues, such as testes, fetal ovaries, and trophoblasts, but have limited expression on other normal tissues in adults and are generally not present on normal reproductive cells (<xref rid="tab1" ref-type="table">Table 1</xref>) [<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B39" ref-type="bibr">39</xref>]. CGAs, such as melanoma-associated antigen 3 (MAGE-A3) and NY-ESO-1 antigen, are selectively expressed by various cancers [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>]. However, attempts to target CGAs have met hurdles. For example, targeting MAGE-A3 resulted in severe neurological toxicity and death [<xref rid="B42" ref-type="bibr">42</xref>].</p><p>Some cancers have been associated with virus infection, and the viral-encoded antigens comprising the viral open reading frames are present in the tumors only but not the normal cells (<xref rid="tab1" ref-type="table">Table 1</xref>). The viral oncogenes encode oncoproteins and cause cell transformation and tumorigenesis, such as Merkel cell polyomavirus- (MCPyV-) associated Merkel cell carcinoma (MCC) and human papillomavirus- (HPV-) associated cervical cancer or oropharyngeal cancer [<xref rid="B43" ref-type="bibr">43</xref>&#x02013;<xref rid="B45" ref-type="bibr">45</xref>]. Targeting virus-associated antigens has been considered to be one of the effective methods for treating cancers [<xref rid="B46" ref-type="bibr">46</xref>&#x02013;<xref rid="B48" ref-type="bibr">48</xref>]. Nevertheless, some virus-associated antigens showed ability to escape from the immune detection of the host [<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>].</p><p>Tumor-specific antigens (TSAs; neoantigens) arise from nonsynonymous mutations and other genetic alterations in cancer cells (<xref rid="tab1" ref-type="table">Table 1</xref>). Neoantigens are mutated peptides been presented by HLA on the cell surface and subsequently recognized by the immune system. TSAs are theoretically more attractive therapeutic targets because they are different from the germline and seen as nonself by the immune system. Because normal cells do not express TSAs, neoantigen-specific immune reactions are not subject to central and peripheral tolerance. In addition, targeting TSAs should be less likely to induce autoimmunity. As a result, neoantigens appear to represent the ideal targets for therapeutic cancer vaccine and T cell-based cancer immunotherapy. Several neoantigens have been identified from different types of cancers, including melanoma, lung cancer, hepatoma, and renal cancers [<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>].</p></sec><sec id="sec4"><title>4. Categories of Cancer Vaccines</title><p>With the development of technologies of next-generation sequencing (NGS), it becomes apparent that human cancers are very complex, bearing thousands of mutations. By the application of platforms of immune repertoire, increasing evidence reveals that some of the tumor antigens could be recognized by the immune repertoire. Now, there are different prediction algorithms and software for the epitope mapping and MHC/neoantigen binding [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B53" ref-type="bibr">53</xref>]. Different kinds of cancer vaccines could be designed to target diverse tumor antigens, including shared antigens or private epitopes.</p><p>There are three broad types of cancer vaccines, designed in the forms of cells, proteins/peptides, and genes (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Regarding cell-based cancer vaccines, there are (1) autologous or allogeneic whole tumor cell vaccine and (2) autologous dendritic cells (DC), pulsed or transfected with tumor antigens in different forms, such as tumor lysates, purified proteins, peptides, DNA, or RNA [<xref rid="B54" ref-type="bibr">54</xref>]. When using the whole tumor cells as the antigens, the cells could be inactivated by heat, chemicals, or radiation. There are different kinds of cancer vaccines using whole tumor cells, e.g., OncoVAX (Vaccinogen) for colon cancer, Reniale (LipoNova) for renal cancer, and GVAX for prostate cancer [<xref rid="B55" ref-type="bibr">55</xref>&#x02013;<xref rid="B57" ref-type="bibr">57</xref>]. The autologous or allogenic whole tumor cells can be genetically modified to produce immune molecules, e.g., Lucanix (belagenpumatucel-L from NovaRx) for NSCLC [<xref rid="B58" ref-type="bibr">58</xref>]. The phase III study of Lucanix (belagenpumatucel-L from NovaRx), however, failed to meet the endpoint in NSCLC [<xref rid="B58" ref-type="bibr">58</xref>]. Since the main disadvantage of whole tumor cell-cancer vaccine is nonspecificity, targeting TAA as the component of the cell-based vaccine may improve the anticancer effect. For example, the dendritic cell vaccine, provenge (sipuleucel-T), targeting PAP for metastatic castration-resistant prostate cancer, was the first FDA-approved cell-based cancer vaccine in 2010 [<xref rid="B59" ref-type="bibr">59</xref>]. Nevertheless, cell-based vaccines also have the limitations of the high-cost, time-consuming, and large-scale manufacturing production for individual patients [<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B61" ref-type="bibr">61</xref>].</p><p>Protein/peptide-based vaccines could be composed of TAAs, CGAs, virus-associated antigens, or TSAs, with different adjuvants. The synthetic peptide vaccines are usually composed of 20&#x02013;30 amino acids targeting the specific epitopes of tumor antigens. Furthermore, the tumor antigens could be modified to fuse or mix with cytokines, antibodies, or immunogenic peptides in the protein/peptide-based cancer vaccines, e.g., Oncophage for kidney cancer, melanoma, and brain cancer and Stimuvax (BLP25 liposome vaccine) targeting MUC1 for NSCLC and breast cancer [<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>]. Peptide vaccines have several advantages, such as easy synthesis with low cost, increased stability, and relative safety. Peptide vaccines have been generally demonstrated in numerous preclinical and clinical studies. However, there are obstacles of peptide vaccines needed to be overcome, which include the limitation of well-known peptide epitopes as vaccine candidates, immune evasion, weak immunogenicity of tumor antigens, and high cost for cGMP manufacturing and production of a fully personalized cancer vaccine [<xref rid="B64" ref-type="bibr">64</xref>&#x02013;<xref rid="B66" ref-type="bibr">66</xref>].</p><p>Gene-based cancer vaccines apply DNA (as plasmids) or RNA (as mRNA), which could be taken up by antigen-presenting cells (APC) and translated into peptides or proteins as cancer-specific antigens to stimulate the immune response. There are different kinds of DNA cancer vaccines, such as mammaglobin-A for breast cancer, PAP for prostate cancer, gp100 and gp75 DNA for melanoma, and VXM01 for pancreatic cancer [<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>]. The major obstacle of gene-based vaccination is the DNA/RNA delivery method and uptake efficiency, consequently limiting the antigen transcription and presentation by APC [<xref rid="B71" ref-type="bibr">71</xref>]. Although electroporation or viral vectors showed higher efficiency to deliver the DNA or RNA into cells, both methods are difficult to be applied in clinical practice [<xref rid="B72" ref-type="bibr">72</xref>&#x02013;<xref rid="B75" ref-type="bibr">75</xref>]. For example, the clinically approved devices for electroporation are available; however, patients' compliance has limited the use [<xref rid="B73" ref-type="bibr">73</xref>]. Regarding the virus-mediated delivery, it should be carefully considered for the potential side effects related to the administration of live virus together with the decreased efficiency of the presence of antiviral neutralizing antibodies in patients [<xref rid="B72" ref-type="bibr">72</xref>].</p></sec><sec id="sec5"><title>5. Preclinical and Clinical Trials Applying Neoantigen-Based Cancer Vaccines</title><p>The number of somatic mutations ranges from a few dozens to several tens of thousands in an individual tumor. With the development of NGS technologies, the highly heterogeneous neoantigens of tumor cells could be characterized. The cancer vaccine is a relatively safe and effective therapy compared to other methods of cancer treatments. To generate the personalized cancer vaccine, the somatic mutations of cancer cells could be identified by the whole exome sequencing via the comparison of the genomic DNA data of excised tumor tissue and peripheral blood mononuclear cells (PBMC) of an individual. According to the profile of detected tumor mutations, the personalized cancer vaccine could be designed to target the specific epitopes of neoantigens against cancers. The personalized cancer vaccine may consist of the synthetic peptides or genes encoding the shared tumor antigens, or private neoantigens, with the presence of adjuvants such as poly-ICLC, GM-CSF, and BCG (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Personalized cancer may be used with the combination of other therapeutics, e.g., ICI, chemotherapy, or radiation therapy.</p><p>Based on the theory of tumor-immune cell interaction, the personalized cancer vaccination works to activate the immune system and kill cancers (<xref ref-type="fig" rid="fig2">Figure 2</xref>) [<xref rid="B76" ref-type="bibr">76</xref>]. First, the neoantigens from the cancer vaccine or died cancer cells are captured by APCs. Next, the activated APCs migrate to the lymph nodes and the MHC molecules present the neoantigens to T lymphocytes. The specific TCR recognizes the neoantigens, resulting in the priming and activation of T cell immunity. Neoantigen-specific T cells are then expanded, traffic and infiltrate to the tumor microenvironment. These expanded T cells specifically bind to the neoantigens of cancer cells via the interaction of the TCR/neoantigen/MHC complex. The CD4-positive T cells augment the immune response against cancers, and CD8-positive cytotoxic T lymphocytes (CTL) directly kill the cancer cells through the degranulation of granzyme, granulysin, or perforin. The lysed tumor cells release more neoantigens, which elicit the adaptive immune memory response and lead to the expansion of molecularly heterogeneous T cells against cancers (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>In the preclinical studies of the tumor vaccination using a mouse model, Castle et al. explored the mutanome and identified candidate mutated epitopes by whole exome sequencing of the B16F10 murine melanoma (46). Fifty selected mutated gene coding peptides were vaccinated to mice, and 11 of 50 peptides demonstrated immunogenicity and induced immune responses (46). The mutated Kif18b (K739 N) was the dominant mutated antigen, and mice immunized with mutated Kif18b peptide showed decreased tumor progression and improved survival [<xref rid="B77" ref-type="bibr">77</xref>]. Yadav et al. predicted the immunogenic tumor mutations by combining mass spectrometry and exome sequencing (47). MC-38 tumor-bearing mice, which were injected with the mutated peptide vaccine (Adpgk, Reps1, and Dpagt1), showed the suppression of tumor growth [<xref rid="B78" ref-type="bibr">78</xref>]. Castle et al. developed a synthetic RNA pentatope vaccine (36). Each pentatope contained five 27-mer minigenes, including the mutated amino acids in the center, and each pentatope was fused to another by 10-mer glycine-serine linker (36). The CT26 tumor-bearing mice were vaccinated with the RNA pentatope, and slow disease progression and improved survival were observed (36). This study suggests that mutant MHC class II epitopes are more immunogenic and drive therapeutic immune response to cancer than that of class I epitopes.</p><p>There are clinical trials evaluating the safety and efficacy of personalized cancer vaccines. Some of the clinical trials have shown encouraging results. For example, Carreno et al. identified somatic mutations in tumors from 3 patients with melanoma by whole exome sequencing (48). The authors used an HLA binding prediction algorithm to initially filter the candidate <italic>HLA-A</italic><sup>&#x02217;</sup><italic>02&#x02009;:&#x02009;01</italic> epitopes containing residues arising from mutations and then evaluated the MHC-epitope binding using competitive assays. The three patients received autologous dendritic cells pulsed with the top 7 neoantigen peptides, which showed higher binding affinity to the <italic>HLA-A</italic><sup>&#x02217;</sup><italic>02&#x02009;:&#x02009;01</italic>. They found that dendritic cell neoantigen vaccine increased the diversity of melanoma neoantigen-specific T cells (48). These neoantigens could be endogenously processed and presented to T cells, and the T lymphocytes elicited by vaccination could recognize the target cells transfected with the corresponding tandem minigene constructs [<xref rid="B79" ref-type="bibr">79</xref>]. Recently, Ott et al. enrolled 6 patients with melanoma and identified the tumor-specific mutations by NGS [<xref rid="B33" ref-type="bibr">33</xref>]. To make the personalized peptide vaccines, the authors predicted the neoantigens which could bind to the individual MHC proteins by algorithms. Each patient was vaccinated using the synthetic long peptides representing up to 20 predicted personal tumor neoantigens. The vaccination induced polyfunctional CD4<sup>+</sup> and CD8<sup>+</sup> T cells targeting 58 (60%) and 15 (16%) of the 97 unique neoantigens used across patients [<xref rid="B33" ref-type="bibr">33</xref>]. These T cells could discriminate mutated and wild-type antigens, and some of them could directly recognize autologous tumor [<xref rid="B33" ref-type="bibr">33</xref>]. Four of 6 patients had no recurrence at 25 months after vaccination, and the other two patients with recurrent disease were subsequently treated with anti-PD-1 therapy and experienced complete tumor regression [<xref rid="B33" ref-type="bibr">33</xref>]. In addition, Sahin et al. showed that personalized RNA mutanome vaccines elicited poly-specific therapeutic immunity against melanoma [<xref rid="B32" ref-type="bibr">32</xref>]. This study applied a process comprising the comprehensive identification of individual mutations, computational prediction of neoantigens with high binding affinity to MHC proteins, and designing and manufacturing of an RNA-based vaccine unique for each patient [<xref rid="B32" ref-type="bibr">32</xref>]. All patients developed T cell response against multiple vaccine neoantigens [<xref rid="B32" ref-type="bibr">32</xref>]. The cumulative rate of metastatic events was significantly reduced after the injection of vaccine, resulting in a sustained progression-free survival [<xref rid="B32" ref-type="bibr">32</xref>]. Two of 5 patients with metastatic disease had vaccine-related objective response, and a patient developed a complete response to vaccination in combination with PD-1 blockade therapy [<xref rid="B32" ref-type="bibr">32</xref>]. These promising results demonstrate that personalized neoantigen cancer vaccine opens a new path to cure the disease.</p></sec><sec id="sec6"><title>6. Conclusion and Future Perspectives</title><p>Cancer vaccine composed of unique tumor antigens specifically forces the immune system to recognize the malignancies, which could be used alone or in combination with other therapies. Among the different kinds of tumor antigens, neoantigens are ideal therapeutic targets for the design of cancer vaccine as they are tumor-specific and have the lowest risks of autoimmunity. The neoantigen-based cancer vaccines showed the induction of de novo T cell clones that detected multiple individual-specific neoantigens and recognized endogenously processed antigens and autologous tumor cells [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. When the encouraging results of personalized cancer vaccines are accumulating, there are some obstacles needing to overcome. Some cancers are &#x0201c;cold tumors,&#x0201d; e.g., pancreatic cancers and colorectal cancers, showing low response rates to immunotherapies. How to use personalized cancer vaccines to increase the reactive T cells in the microenvironment and combine with other therapies to have synergy effects on &#x0201c;cold tumors&#x0201d; needs further investigation. Another concern is the heterogeneity of tumor and immune escape. In an individual patient, the same types of neoantigens may be expressed on some, but not all tumor cells, which may cause cancers to escape from immunotherapy. One potential approach to solve this problem is to target multiple neoantigens of a diversity of malignant clones per patient, as demonstrated in the previous studies [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. Therefore, all tumor cells could be destroyed at the same time of the treatment course, and the cancer vaccine minimizes the chance of tumor escape by the loss of antigens [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. Lastly, the pharmacoeconomics is also an important issue for implementing personalized neoantigen cancer vaccine into clinic practice. The individualized vaccine is still expensive due to the cost for genome sequencing and manufacturing of small and personalized-specific GMP drug product batches. However, the expense for personalized cancer vaccine may reduce following the development of improved methods for predicting antigen presentation, the process of commercialization, full automation, and optimization of manufacturing processes. After having more understandings of the cancer immunology, the cancer vaccine may be designed to target the driver mutations or shared antigens of different tumor types or individuals, to increase the therapeutic efficiency, and to reduce the expense of manufacturing [<xref rid="B80" ref-type="bibr">80</xref>]. In conclusion, there are increasing evidence demonstrating the feasibility, safety, and immunogenicity of the personalized cancer vaccine in the treatment of cancer patients. The personalized cancer vaccine could work alone or in combination with other therapies to enhance the strength and persistence of antitumor effects, increase the survival rates and quality of life, and ultimately improve the efficacy of cancer treatments in the patients. It is anticipated that personalized cancer vaccine will make precision medicine to be available and affordable for most of patient population in the near future.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank the National Science Council of Taiwan (MOST104-2314-B-182A-148-MY3, MOST104-2325-B-182A-006, MOST104-2320-B-010-036-MY3, and MOST105-2628-B-010-007-MY3) for kindly supporting this work.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>ACT:</term><def><p>Adoptive cell transfer</p></def></def-item><def-item><term>APC:</term><def><p>Antigen-presenting cells</p></def></def-item><def-item><term>CAR-T therapy:</term><def><p>Chimeric antigen receptors-T cell therapy</p></def></def-item><def-item><term>CGAs:</term><def><p>Cancer germline antigens</p></def></def-item><def-item><term>CTL:</term><def><p>Cytotoxic T lymphocyte</p></def></def-item><def-item><term>HLA:</term><def><p>Human leukocyte antigen</p></def></def-item><def-item><term>ICI:</term><def><p>Immune checkpoint inhibitors</p></def></def-item><def-item><term>irAE:</term><def><p>Immune-related adverse events</p></def></def-item><def-item><term>MHC:</term><def><p>Major histocompatibility complex</p></def></def-item><def-item><term>NSCLC:</term><def><p>Nonsmall cell lung cancer</p></def></def-item><def-item><term>NGS:</term><def><p>Next-generation sequencing</p></def></def-item><def-item><term>TAA:</term><def><p>Tumor-associated antigen</p></def></def-item><def-item><term>TCR:</term><def><p>T cell receptor</p></def></def-item><def-item><term>TIL:</term><def><p>Tumor-infiltrating lymphocytes</p></def></def-item><def-item><term>TSA:</term><def><p>Tumor-specific antigen.</p></def></def-item></def-list></glossary><sec><title>Conflicts of Interest</title><p>All authors declare that no conflict of interest exists.</p></sec><sec><title>Authors' Contributions</title><p>Ren-You Pan and Shuen-Iu Hung are responsible for the conception and design. Shuen-Iu Hung and Wen-Hung Chung are responsible for the administrative support. All authors provided the study materials or patients; collected, assembled, analyzed, and interpreted the data; and approved the final manuscript. Ren-You Pan and Wen-Hung Chung contribute equally to this work.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbani</surname><given-names>R.</given-names></name><name><surname>Akdemir</surname><given-names>K. C.</given-names></name><name><surname>Aksoy</surname><given-names>B. A.</given-names></name><etal/></person-group><article-title>Genomic classification of cutaneous melanoma</article-title><source><italic toggle="yes">Cell</italic></source><year>2015</year><volume>161</volume><issue>7</issue><fpage>1681</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.044</pub-id><pub-id pub-id-type="other">2-s2.0-84935009372</pub-id><?supplied-pmid 26091043?><pub-id pub-id-type="pmid">26091043</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>M. S.</given-names></name><name><surname>Stojanov</surname><given-names>P.</given-names></name><name><surname>Mermel</surname><given-names>C. H.</given-names></name><etal/></person-group><article-title>Discovery and saturation analysis of cancer genes across 21 tumour types</article-title><source><italic toggle="yes">Nature</italic></source><year>2014</year><volume>505</volume><issue>7484</issue><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/nature12912</pub-id><pub-id pub-id-type="other">2-s2.0-84892833777</pub-id><?supplied-pmid 24390350?><pub-id pub-id-type="pmid">24390350</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>M. S.</given-names></name><name><surname>Stojanov</surname><given-names>P.</given-names></name><name><surname>Polak</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes</article-title><source><italic toggle="yes">Nature</italic></source><year>2013</year><volume>499</volume><issue>7457</issue><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nature12213</pub-id><pub-id pub-id-type="other">2-s2.0-84880507665</pub-id><?supplied-pmid 23770567?><pub-id pub-id-type="pmid">23770567</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>L. D.</given-names></name><name><surname>Parsons</surname><given-names>D. W.</given-names></name><name><surname>Jones</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The genomic landscapes of human breast and colorectal cancers</article-title><source><italic toggle="yes">Science</italic></source><year>2007</year><volume>318</volume><issue>5853</issue><fpage>1108</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1126/science.1145720</pub-id><pub-id pub-id-type="other">2-s2.0-36248962105</pub-id><?supplied-pmid 17932254?><pub-id pub-id-type="pmid">17932254</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bais</surname><given-names>P.</given-names></name><name><surname>Namburi</surname><given-names>S.</given-names></name><name><surname>Gatti</surname><given-names>D. M.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Chuang</surname><given-names>J. H.</given-names></name></person-group><article-title>CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens</article-title><source><italic toggle="yes">Bioinformatics</italic></source><year>2017</year><volume>33</volume><issue>19</issue><fpage>3110</fpage><lpage>3112</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btx375</pub-id><pub-id pub-id-type="other">2-s2.0-85030693588</pub-id><?supplied-pmid 28605406?><pub-id pub-id-type="pmid">28605406</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodi</surname><given-names>F. S.</given-names></name><name><surname>O'Day</surname><given-names>S. J.</given-names></name><name><surname>McDermott</surname><given-names>D. F.</given-names></name><etal/></person-group><article-title>Improved survival with ipilimumab in patients with metastatic melanoma</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2010</year><volume>363</volume><issue>8</issue><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1003466</pub-id><pub-id pub-id-type="other">2-s2.0-77954801079</pub-id><?supplied-pmid 20525992?><pub-id pub-id-type="pmid">20525992</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>C.</given-names></name><name><surname>Thomas</surname><given-names>L.</given-names></name><name><surname>Bondarenko</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Ipilimumab plus dacarbazine for previously untreated metastatic melanoma</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2011</year><volume>364</volume><issue>26</issue><fpage>2517</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1104621</pub-id><pub-id pub-id-type="other">2-s2.0-79959772576</pub-id><?supplied-pmid 21639810?><pub-id pub-id-type="pmid">21639810</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumeister</surname><given-names>S. H.</given-names></name><name><surname>Freeman</surname><given-names>G. J.</given-names></name><name><surname>Dranoff</surname><given-names>G.</given-names></name><name><surname>Sharpe</surname><given-names>A. H.</given-names></name></person-group><article-title>Coinhibitory pathways in immunotherapy for cancer</article-title><source><italic toggle="yes">Annual Review of Immunology</italic></source><year>2016</year><volume>34</volume><issue>1</issue><fpage>539</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112049</pub-id><pub-id pub-id-type="other">2-s2.0-84969850678</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarchoan</surname><given-names>M.</given-names></name><name><surname>Hopkins</surname><given-names>A.</given-names></name><name><surname>Jaffee</surname><given-names>E. M.</given-names></name></person-group><article-title>Tumor mutational burden and response rate to PD-1 inhibition</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2017</year><volume>377</volume><issue>25</issue><fpage>2500</fpage><lpage>2501</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1713444</pub-id><pub-id pub-id-type="other">2-s2.0-85039783649</pub-id><?supplied-pmid 29262275?><pub-id pub-id-type="pmid">29262275</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vranic</surname><given-names>S.</given-names></name></person-group><article-title>Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: a comment on recent advances</article-title><source><italic toggle="yes">Bosnian Journal of Basic Medical Sciences</italic></source><year>2017</year><volume>17</volume><issue>3</issue><fpage>274</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.17305/bjbms.2017.2366</pub-id><pub-id pub-id-type="other">2-s2.0-85028591799</pub-id><?supplied-pmid 28812534?><pub-id pub-id-type="pmid">28812534</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>V.</given-names></name><name><surname>Murphy</surname><given-names>A.</given-names></name><name><surname>le</surname><given-names>D. T.</given-names></name><name><surname>Diaz</surname><given-names>L. A.</given-names><suffix>Jr</suffix></name></person-group><article-title>Mismatch repair deficiency and response to immune checkpoint blockade</article-title><source><italic toggle="yes">The Oncologist</italic></source><year>2016</year><volume>21</volume><issue>10</issue><fpage>1200</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2016-0046</pub-id><pub-id pub-id-type="other">2-s2.0-84991735355</pub-id><?supplied-pmid 27412392?><pub-id pub-id-type="pmid">27412392</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardoll</surname><given-names>D. M.</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source><italic toggle="yes">Nature Reviews. Cancer</italic></source><year>2012</year><volume>12</volume><issue>4</issue><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrc3239</pub-id><pub-id pub-id-type="other">2-s2.0-84858766182</pub-id><?supplied-pmid 22437870?><pub-id pub-id-type="pmid">22437870</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fecher</surname><given-names>L. A.</given-names></name><name><surname>Agarwala</surname><given-names>S. S.</given-names></name><name><surname>Hodi</surname><given-names>F. S.</given-names></name><name><surname>Weber</surname><given-names>J. S.</given-names></name></person-group><article-title>Ipilimumab and its toxicities: a multidisciplinary approach</article-title><source><italic toggle="yes">The Oncologist</italic></source><year>2013</year><volume>18</volume><issue>6</issue><fpage>733</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2012-0483</pub-id><pub-id pub-id-type="other">2-s2.0-84879477789</pub-id><?supplied-pmid 23774827?><pub-id pub-id-type="pmid">23774827</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geyer</surname><given-names>M. B.</given-names></name></person-group><article-title>First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2018</year></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullard</surname><given-names>A.</given-names></name></person-group><article-title>FDA approves first CAR T therapy</article-title><source><italic toggle="yes">Nature Reviews Drug Discovery</italic></source><year>2017</year><volume>16</volume><issue>10</issue><fpage>p. 669</fpage><pub-id pub-id-type="doi">10.1038/nrd.2017.196</pub-id><pub-id pub-id-type="other">2-s2.0-85032490661</pub-id><?supplied-pmid 28959949?><pub-id pub-id-type="pmid">28959949</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettitt</surname><given-names>D.</given-names></name><name><surname>Arshad</surname><given-names>Z.</given-names></name><name><surname>Smith</surname><given-names>J.</given-names></name><name><surname>Stanic</surname><given-names>T.</given-names></name><name><surname>Hollander</surname><given-names>G.</given-names></name><name><surname>Brindley</surname><given-names>D.</given-names></name></person-group><article-title>CAR-T cells: a systematic review and mixed methods analysis of the clinical trial landscape</article-title><source><italic toggle="yes">Molecular Therapy</italic></source><year>2018</year><volume>26</volume><issue>2</issue><fpage>342</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.10.019</pub-id><pub-id pub-id-type="other">2-s2.0-85039072475</pub-id><?supplied-pmid 29248427?><pub-id pub-id-type="pmid">29248427</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>J.</given-names></name><name><surname>Schussler-Lenz</surname><given-names>M.</given-names></name><name><surname>Bondanza</surname><given-names>A.</given-names></name><name><surname>Buchholz</surname><given-names>C. J.</given-names></name></person-group><article-title>Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts</article-title><source><italic toggle="yes">EMBO Molecular Medicine</italic></source><year>2017</year><volume>9</volume><issue>9</issue><fpage>1183</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.15252/emmm.201607485</pub-id><pub-id pub-id-type="other">2-s2.0-85026540484</pub-id><?supplied-pmid 28765140?><pub-id pub-id-type="pmid">28765140</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grupp</surname><given-names>S. A.</given-names></name><name><surname>Kalos</surname><given-names>M.</given-names></name><name><surname>Barrett</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Chimeric antigen receptor-modified T cells for acute lymphoid leukemia</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2013</year><volume>368</volume><issue>16</issue><fpage>1509</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1215134</pub-id><pub-id pub-id-type="other">2-s2.0-84876325876</pub-id><?supplied-pmid 23527958?><pub-id pub-id-type="pmid">23527958</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maude</surname><given-names>S. L.</given-names></name><name><surname>Frey</surname><given-names>N.</given-names></name><name><surname>Shaw</surname><given-names>P. A.</given-names></name><etal/></person-group><article-title>Chimeric antigen receptor T cells for sustained remissions in leukemia</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2014</year><volume>371</volume><issue>16</issue><fpage>1507</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1407222</pub-id><pub-id pub-id-type="other">2-s2.0-84908073316</pub-id><?supplied-pmid 25317870?><pub-id pub-id-type="pmid">25317870</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname><given-names>D. J.</given-names></name><name><surname>Godolphin</surname><given-names>W.</given-names></name><name><surname>Jones</surname><given-names>L. A.</given-names></name><etal/></person-group><article-title>Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer</article-title><source><italic toggle="yes">Science</italic></source><year>1989</year><volume>244</volume><issue>4905</issue><fpage>707</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1126/science.2470152</pub-id><pub-id pub-id-type="other">2-s2.0-0024337144</pub-id><?supplied-pmid 2470152?><pub-id pub-id-type="pmid">2470152</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newick</surname><given-names>K.</given-names></name><name><surname>Moon</surname><given-names>E.</given-names></name><name><surname>Albelda</surname><given-names>S. M.</given-names></name></person-group><article-title>Chimeric antigen receptor T-cell therapy for solid tumors</article-title><source><italic toggle="yes">Molecular Therapy - Oncolytics</italic></source><year>2016</year><volume>3, article 16006</volume><pub-id pub-id-type="doi">10.1038/mto.2016.6</pub-id><pub-id pub-id-type="other">2-s2.0-85044231668</pub-id><?supplied-pmid 27162934?><pub-id pub-id-type="pmid">27162934</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>A. L.</given-names></name><name><surname>Wang</surname><given-names>X. C.</given-names></name><name><surname>Lu</surname><given-names>Y. J.</given-names></name><name><surname>Lu</surname><given-names>X. J.</given-names></name><name><surname>Sun</surname><given-names>B.</given-names></name></person-group><article-title>Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities</article-title><source><italic toggle="yes">Oncotarget</italic></source><year>2017</year><volume>8</volume><issue>52</issue><fpage>90521</fpage><lpage>90531</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.19361</pub-id><pub-id pub-id-type="other">2-s2.0-85029804184</pub-id><?supplied-pmid 29163850?><pub-id pub-id-type="pmid">29163850</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>L.</given-names></name><name><surname>Kyewski</surname><given-names>B.</given-names></name><name><surname>Allen</surname><given-names>P. M.</given-names></name><name><surname>Hogquist</surname><given-names>K. A.</given-names></name></person-group><article-title>Positive and negative selection of the T cell repertoire: what thymocytes see (and don&#x02019;t see)</article-title><source><italic toggle="yes">Nature Reviews. Immunology</italic></source><year>2014</year><volume>14</volume><issue>6</issue><fpage>377</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1038/nri3667</pub-id><pub-id pub-id-type="other">2-s2.0-84901487911</pub-id><?supplied-pmid 24830344?><pub-id pub-id-type="pmid">24830344</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>E.</given-names></name><name><surname>Turcotte</surname><given-names>S.</given-names></name><name><surname>Gros</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer</article-title><source><italic toggle="yes">Science</italic></source><year>2014</year><volume>344</volume><issue>6184</issue><fpage>641</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1126/science.1251102</pub-id><pub-id pub-id-type="other">2-s2.0-84900301377</pub-id><?supplied-pmid 24812403?><pub-id pub-id-type="pmid">24812403</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Rooij</surname><given-names>N.</given-names></name><name><surname>van Buuren</surname><given-names>M. M.</given-names></name><name><surname>Philips</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma</article-title><source><italic toggle="yes">Journal of Clinical Oncology</italic></source><year>2013</year><volume>31</volume><issue>32</issue><fpage>e439</fpage><lpage>e442</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.47.7521</pub-id><pub-id pub-id-type="other">2-s2.0-84872841412</pub-id><?supplied-pmid 24043743?><pub-id pub-id-type="pmid">24043743</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubin</surname><given-names>M. M.</given-names></name><name><surname>Artyomov</surname><given-names>M. N.</given-names></name><name><surname>Mardis</surname><given-names>E. R.</given-names></name><name><surname>Schreiber</surname><given-names>R. D.</given-names></name></person-group><article-title>Tumor neoantigens: building a framework for personalized cancer immunotherapy</article-title><source><italic toggle="yes">The Journal of Clinical Investigation</italic></source><year>2015</year><volume>125</volume><issue>9</issue><fpage>3413</fpage><lpage>3421</lpage><pub-id pub-id-type="doi">10.1172/JCI80008</pub-id><pub-id pub-id-type="other">2-s2.0-84941710020</pub-id><?supplied-pmid 26258412?><pub-id pub-id-type="pmid">26258412</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname><given-names>T. N.</given-names></name><name><surname>Schreiber</surname><given-names>R. D.</given-names></name></person-group><article-title>Neoantigens in cancer immunotherapy</article-title><source><italic toggle="yes">Science</italic></source><year>2015</year><volume>348</volume><issue>6230</issue><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4971</pub-id><pub-id pub-id-type="other">2-s2.0-84928770388</pub-id><?supplied-pmid 25838375?><pub-id pub-id-type="pmid">25838375</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blankenstein</surname><given-names>T.</given-names></name><name><surname>Leisegang</surname><given-names>M.</given-names></name><name><surname>Uckert</surname><given-names>W.</given-names></name><name><surname>Schreiber</surname><given-names>H.</given-names></name></person-group><article-title>Targeting cancer-specific mutations by T cell receptor gene therapy</article-title><source><italic toggle="yes">Current Opinion in Immunology</italic></source><year>2015</year><volume>33</volume><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2015.02.005</pub-id><pub-id pub-id-type="other">2-s2.0-84923690696</pub-id><?supplied-pmid 25728991?><pub-id pub-id-type="pmid">25728991</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stronen</surname><given-names>E.</given-names></name><name><surname>Toebes</surname><given-names>M.</given-names></name><name><surname>Kelderman</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Targeting of cancer neoantigens with donor-derived T cell receptor repertoires</article-title><source><italic toggle="yes">Science</italic></source><year>2016</year><volume>352</volume><issue>6291</issue><fpage>1337</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1126/science.aaf2288</pub-id><pub-id pub-id-type="other">2-s2.0-84969764539</pub-id><?supplied-pmid 27198675?><pub-id pub-id-type="pmid">27198675</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bethune</surname><given-names>M. T.</given-names></name><name><surname>Joglekar</surname><given-names>A. V.</given-names></name></person-group><article-title>Personalized T cell-mediated cancer immunotherapy: progress and challenges</article-title><source><italic toggle="yes">Current Opinion in Biotechnology</italic></source><year>2017</year><volume>48</volume><fpage>142</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2017.03.024</pub-id><pub-id pub-id-type="other">2-s2.0-85019030781</pub-id><?supplied-pmid 28494274?><pub-id pub-id-type="pmid">28494274</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritsch</surname><given-names>E. F.</given-names></name><name><surname>Hacohen</surname><given-names>N.</given-names></name><name><surname>Wu</surname><given-names>C. J.</given-names></name></person-group><article-title>Personal neoantigen cancer vaccines: the momentum builds</article-title><source><italic toggle="yes">OncoImmunology</italic></source><year>2014</year><volume>3</volume><issue>6, article e29311</issue><pub-id pub-id-type="doi">10.4161/onci.29311</pub-id><pub-id pub-id-type="other">2-s2.0-84906489246</pub-id><?supplied-pmid 25101225?><pub-id pub-id-type="pmid">25101225</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahin</surname><given-names>U.</given-names></name><name><surname>Derhovanessian</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</article-title><source><italic toggle="yes">Nature</italic></source><year>2017</year><volume>547</volume><issue>7662</issue><fpage>222</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/nature23003</pub-id><pub-id pub-id-type="other">2-s2.0-85024396858</pub-id><?supplied-pmid 28678784?><pub-id pub-id-type="pmid">28678784</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>P. A.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Keskin</surname><given-names>D. B.</given-names></name><etal/></person-group><article-title>An immunogenic personal neoantigen vaccine for patients with melanoma</article-title><source><italic toggle="yes">Nature</italic></source><year>2017</year><volume>547</volume><issue>7662</issue><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/nature22991</pub-id><pub-id pub-id-type="other">2-s2.0-85024377220</pub-id><?supplied-pmid 28678778?><pub-id pub-id-type="pmid">28678778</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butts</surname><given-names>C.</given-names></name><name><surname>Socinski</surname><given-names>M. A.</given-names></name><name><surname>Mitchell</surname><given-names>P. L.</given-names></name><etal/></person-group><article-title>Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial</article-title><source><italic toggle="yes">The Lancet Oncology</italic></source><year>2014</year><volume>15</volume><issue>1</issue><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70510-2</pub-id><pub-id pub-id-type="other">2-s2.0-84891373760</pub-id><?supplied-pmid 24331154?><pub-id pub-id-type="pmid">24331154</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulie</surname><given-names>P. G.</given-names></name><name><surname>Van den Eynde</surname><given-names>B. J.</given-names></name><name><surname>van der Bruggen</surname><given-names>P.</given-names></name><name><surname>Boon</surname><given-names>T.</given-names></name></person-group><article-title>Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy</article-title><source><italic toggle="yes">Nature Reviews. Cancer</italic></source><year>2014</year><volume>14</volume><issue>2</issue><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/nrc3670</pub-id><pub-id pub-id-type="other">2-s2.0-84894559188</pub-id><?supplied-pmid 24457417?><pub-id pub-id-type="pmid">24457417</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>J. D.</given-names></name><name><surname>Harris</surname><given-names>D. T.</given-names></name><name><surname>Kranz</surname><given-names>D. M.</given-names></name></person-group><article-title>TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity</article-title><source><italic toggle="yes">Current Opinion in Immunology</italic></source><year>2015</year><volume>33</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2015.01.003</pub-id><pub-id pub-id-type="other">2-s2.0-84921479955</pub-id><?supplied-pmid 25618219?><pub-id pub-id-type="pmid">25618219</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleksic</surname><given-names>M.</given-names></name><name><surname>Liddy</surname><given-names>N.</given-names></name><name><surname>Molloy</surname><given-names>P. E.</given-names></name><etal/></person-group><article-title>Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies</article-title><source><italic toggle="yes">European Journal of Immunology</italic></source><year>2012</year><volume>42</volume><issue>12</issue><fpage>3174</fpage><lpage>3179</lpage><pub-id pub-id-type="doi">10.1002/eji.201242606</pub-id><pub-id pub-id-type="other">2-s2.0-84871338258</pub-id><?supplied-pmid 22949370?><pub-id pub-id-type="pmid">22949370</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>J. P.</given-names></name><name><surname>Gubin</surname><given-names>M. M.</given-names></name><name><surname>Schreiber</surname><given-names>R. D.</given-names></name></person-group><article-title>The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer</article-title><source><italic toggle="yes">Advances in Immunology</italic></source><year>2016</year><volume>130</volume><fpage>25</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/bs.ai.2016.01.001</pub-id><pub-id pub-id-type="other">2-s2.0-84957928309</pub-id><pub-id pub-id-type="pmid">26922999</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>A. J. G.</given-names></name><name><surname>Caballero</surname><given-names>O. L.</given-names></name><name><surname>Jungbluth</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>Y. T.</given-names></name><name><surname>Old</surname><given-names>L. J.</given-names></name></person-group><article-title>Cancer/testis antigens, gametogenesis and cancer</article-title><source><italic toggle="yes">Nature Reviews. Cancer</italic></source><year>2005</year><volume>5</volume><issue>8</issue><fpage>615</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1038/nrc1669</pub-id><pub-id pub-id-type="other">2-s2.0-23144464171</pub-id><?supplied-pmid 16034368?><pub-id pub-id-type="pmid">16034368</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chomez</surname><given-names>P.</given-names></name><name><surname>De Backer</surname><given-names>O.</given-names></name><name><surname>Bertrand</surname><given-names>M.</given-names></name><name><surname>De Plaen</surname><given-names>E.</given-names></name><name><surname>Boon</surname><given-names>T.</given-names></name><name><surname>Lucas</surname><given-names>S.</given-names></name></person-group><article-title>An overview of the MAGE gene family with the identification of all human members of the family</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2001</year><volume>61</volume><issue>14</issue><fpage>5544</fpage><lpage>5551</lpage><?supplied-pmid 11454705?><pub-id pub-id-type="pmid">11454705</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnjatic</surname><given-names>S.</given-names></name><name><surname>Nishikawa</surname><given-names>H.</given-names></name><name><surname>Jungbluth</surname><given-names>A. A.</given-names></name><etal/></person-group><article-title>NY-ESO-1: review of an immunogenic tumor antigen</article-title><source><italic toggle="yes">Advances in Cancer Research</italic></source><year>2006</year><volume>95</volume><fpage>1</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/S0065-230X(06)95001-5</pub-id><pub-id pub-id-type="other">2-s2.0-33746211234</pub-id><pub-id pub-id-type="pmid">16860654</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>R. A.</given-names></name><name><surname>Chinnasamy</surname><given-names>N.</given-names></name><name><surname>Abate-Daga</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy</article-title><source><italic toggle="yes">Journal of Immunotherapy</italic></source><year>2013</year><volume>36</volume><issue>2</issue><fpage>133</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e3182829903</pub-id><pub-id pub-id-type="other">2-s2.0-84873991752</pub-id><?supplied-pmid 23377668?><pub-id pub-id-type="pmid">23377668</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>H.</given-names></name><name><surname>Shuda</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name><name><surname>Moore</surname><given-names>P. S.</given-names></name></person-group><article-title>Clonal integration of a polyomavirus in human Merkel cell carcinoma</article-title><source><italic toggle="yes">Science</italic></source><year>2008</year><volume>319</volume><issue>5866</issue><fpage>1096</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1126/science.1152586</pub-id><pub-id pub-id-type="other">2-s2.0-39749113080</pub-id><?supplied-pmid 18202256?><pub-id pub-id-type="pmid">18202256</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillison</surname><given-names>M. L.</given-names></name><name><surname>Koch</surname><given-names>W. M.</given-names></name><name><surname>Capone</surname><given-names>R. B.</given-names></name><etal/></person-group><article-title>Evidence for a causal association between human papillomavirus and a subset of head and neck cancers</article-title><source><italic toggle="yes">Journal of the National Cancer Institute</italic></source><year>2000</year><volume>92</volume><issue>9</issue><fpage>709</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1093/jnci/92.9.709</pub-id><?supplied-pmid 10793107?><pub-id pub-id-type="pmid">10793107</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walboomers</surname><given-names>J. M. M.</given-names></name><name><surname>Jacobs</surname><given-names>M. V.</given-names></name><name><surname>Manos</surname><given-names>M. M.</given-names></name><etal/></person-group><article-title>Human papillomavirus is a necessary cause of invasive cervical cancer worldwide</article-title><source><italic toggle="yes">The Journal of Pathology</italic></source><year>1999</year><volume>189</volume><issue>1</issue><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9896(199909)189:1&#x0003c;12::AID-PATH431&#x0003e;3.0.CO;2-F</pub-id><?supplied-pmid 10451482?><pub-id pub-id-type="pmid">10451482</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X. G.</given-names></name><name><surname>Revskaya</surname><given-names>E.</given-names></name><name><surname>Bryan</surname><given-names>R. A.</given-names></name><etal/></person-group><article-title>Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2007</year><volume>2</volume><issue>10, article e1114</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0001114</pub-id><pub-id pub-id-type="other">2-s2.0-38849197351</pub-id><?supplied-pmid 17971877?><pub-id pub-id-type="pmid">17971877</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin-Drubin</surname><given-names>M. E.</given-names></name><name><surname>Munger</surname><given-names>K.</given-names></name></person-group><article-title>Viruses associated with human cancer</article-title><source><italic toggle="yes">Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</italic></source><year>2008</year><volume>1782</volume><issue>3</issue><fpage>127</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2007.12.005</pub-id><pub-id pub-id-type="other">2-s2.0-39149130988</pub-id><?supplied-pmid 18201576?><pub-id pub-id-type="pmid">18201576</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuroki</surname><given-names>M.</given-names></name><name><surname>Shirasu</surname><given-names>N.</given-names></name></person-group><article-title>Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens</article-title><source><italic toggle="yes">Anticancer Research</italic></source><year>2014</year><volume>34</volume><issue>8</issue><fpage>4481</fpage><lpage>4488</lpage><?supplied-pmid 25075090?><pub-id pub-id-type="pmid">25075090</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>M.</given-names></name><name><surname>Karrer</surname><given-names>U.</given-names></name><name><surname>Lucas</surname><given-names>A.</given-names></name><name><surname>Klenerman</surname><given-names>P.</given-names></name></person-group><article-title>Viral escape mechanisms--escapology taught by viruses</article-title><source><italic toggle="yes">International Journal of Experimental Pathology</italic></source><year>2001</year><volume>82</volume><issue>5</issue><fpage>269</fpage><lpage>286</lpage><?supplied-pmid 11703537?><pub-id pub-id-type="pmid">11703537</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finlay</surname><given-names>B. B.</given-names></name><name><surname>McFadden</surname><given-names>G.</given-names></name></person-group><article-title>Anti-immunology: evasion of the host immune system by bacterial and viral pathogens</article-title><source><italic toggle="yes">Cell</italic></source><year>2006</year><volume>124</volume><issue>4</issue><fpage>767</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.01.034</pub-id><pub-id pub-id-type="other">2-s2.0-32944462309</pub-id><?supplied-pmid 16497587?><pub-id pub-id-type="pmid">16497587</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takenoyama</surname><given-names>M.</given-names></name><name><surname>Baurain</surname><given-names>J. F.</given-names></name><name><surname>Yasuda</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma</article-title><source><italic toggle="yes">International Journal of Cancer</italic></source><year>2006</year><volume>118</volume><issue>8</issue><fpage>1992</fpage><lpage>1997</lpage><pub-id pub-id-type="doi">10.1002/ijc.21594</pub-id><pub-id pub-id-type="other">2-s2.0-33645239336</pub-id><?supplied-pmid 16287085?><pub-id pub-id-type="pmid">16287085</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Jun</surname><given-names>D. Y.</given-names></name><name><surname>Thomas</surname><given-names>A. M.</given-names></name><etal/></person-group><article-title>Diverse CD8<sup>+</sup> T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2005</year><volume>65</volume><issue>3</issue><fpage>1079</fpage><lpage>1088</lpage><?supplied-pmid 15705910?><pub-id pub-id-type="pmid">15705910</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tappeiner</surname><given-names>E.</given-names></name><name><surname>Finotello</surname><given-names>F.</given-names></name><name><surname>Charoentong</surname><given-names>P.</given-names></name><name><surname>Mayer</surname><given-names>C.</given-names></name><name><surname>Rieder</surname><given-names>D.</given-names></name><name><surname>Trajanoski</surname><given-names>Z.</given-names></name></person-group><article-title>TIminer: NGS data mining pipeline for cancer immunology and immunotherapy</article-title><source><italic toggle="yes">Bioinformatics</italic></source><year>2017</year><volume>33</volume><issue>19</issue><fpage>3140</fpage><lpage>3141</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btx377</pub-id><pub-id pub-id-type="other">2-s2.0-85030697733</pub-id><?supplied-pmid 28633385?><pub-id pub-id-type="pmid">28633385</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galluzzi</surname><given-names>L.</given-names></name><name><surname>Vacchelli</surname><given-names>E.</given-names></name><name><surname>Pedro</surname><given-names>J. M. B. S.</given-names></name><etal/></person-group><article-title>Classification of current anticancer immunotherapies</article-title><source><italic toggle="yes">Oncotarget</italic></source><year>2014</year><volume>5</volume><issue>24</issue><fpage>12472</fpage><lpage>12508</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2998</pub-id><pub-id pub-id-type="other">2-s2.0-84921418427</pub-id><?supplied-pmid 25537519?><pub-id pub-id-type="pmid">25537519</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanna</surname><given-names>M. G.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer</article-title><source><italic toggle="yes">Human Vaccines &#x00026; Immunotherapeutics</italic></source><year>2012</year><volume>8</volume><issue>8</issue><fpage>1156</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.4161/hv.20740</pub-id><pub-id pub-id-type="other">2-s2.0-84866118624</pub-id><?supplied-pmid 22854664?><pub-id pub-id-type="pmid">22854664</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittke</surname><given-names>S.</given-names></name><name><surname>Baxmann</surname><given-names>S.</given-names></name><name><surname>Fahlenkamp</surname><given-names>D.</given-names></name><name><surname>Kiessig</surname><given-names>S. T.</given-names></name></person-group><article-title>Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine</article-title><source><italic toggle="yes">OncoTargets and Therapy</italic></source><year>2016</year><volume>9</volume><fpage>523</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.2147/OTT.S92182</pub-id><pub-id pub-id-type="other">2-s2.0-84957548317</pub-id><?supplied-pmid 26889089?><pub-id pub-id-type="pmid">26889089</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geary</surname><given-names>S. M.</given-names></name><name><surname>Salem</surname><given-names>A. K.</given-names></name></person-group><article-title>Prostate cancer vaccines: update on clinical development</article-title><source><italic toggle="yes">OncoImmunology</italic></source><year>2014</year><volume>2</volume><issue>5, article e24523</issue><pub-id pub-id-type="doi">10.4161/onci.24523</pub-id><pub-id pub-id-type="other">2-s2.0-84885659813</pub-id><?supplied-pmid 23762812?><pub-id pub-id-type="pmid">23762812</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zappa</surname><given-names>C.</given-names></name><name><surname>Mousa</surname><given-names>S. A.</given-names></name></person-group><article-title>Non-small cell lung cancer: current treatment and future advances</article-title><source><italic toggle="yes">Translational Lung Cancer Research</italic></source><year>2016</year><volume>5</volume><issue>3</issue><fpage>288</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.21037/tlcr.2016.06.07</pub-id><pub-id pub-id-type="other">2-s2.0-84977470126</pub-id><?supplied-pmid 27413711?><pub-id pub-id-type="pmid">27413711</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheever</surname><given-names>M. A.</given-names></name><name><surname>Higano</surname><given-names>C. S.</given-names></name></person-group><article-title>PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2011</year><volume>17</volume><issue>11</issue><fpage>3520</fpage><lpage>3526</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-3126</pub-id><pub-id pub-id-type="other">2-s2.0-79957879852</pub-id><?supplied-pmid 21471425?><pub-id pub-id-type="pmid">21471425</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lollini</surname><given-names>P. L.</given-names></name><name><surname>Cavallo</surname><given-names>F.</given-names></name><name><surname>Nanni</surname><given-names>P.</given-names></name><name><surname>Quaglino</surname><given-names>E.</given-names></name></person-group><article-title>The promise of preventive cancer vaccines</article-title><source><italic toggle="yes">Vaccines</italic></source><year>2015</year><volume>3</volume><issue>2</issue><fpage>467</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.3390/vaccines3020467</pub-id><pub-id pub-id-type="other">2-s2.0-85016877170</pub-id><?supplied-pmid 26343198?><pub-id pub-id-type="pmid">26343198</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullins</surname><given-names>D. W.</given-names></name><name><surname>Sheasley</surname><given-names>S. L.</given-names></name><name><surname>Ream</surname><given-names>R. M.</given-names></name><name><surname>Bullock</surname><given-names>T. N. J.</given-names></name><name><surname>Fu</surname><given-names>Y.-X.</given-names></name><name><surname>Engelhard</surname><given-names>V. H.</given-names></name></person-group><article-title>Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control</article-title><source><italic toggle="yes">The Journal of Experimental Medicine</italic></source><year>2003</year><volume>198</volume><issue>7</issue><fpage>1023</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1084/jem.20021348</pub-id><pub-id pub-id-type="other">2-s2.0-0141993954</pub-id><?supplied-pmid 14530375?><pub-id pub-id-type="pmid">14530375</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>di Pietro</surname><given-names>A.</given-names></name><name><surname>Tosti</surname><given-names>G.</given-names></name><name><surname>Ferrucci</surname><given-names>P. F.</given-names></name><name><surname>Testori</surname><given-names>A.</given-names></name></person-group><article-title>Oncophage: step to the future for vaccine therapy in melanoma</article-title><source><italic toggle="yes">Expert Opinion on Biological Therapy</italic></source><year>2008</year><volume>8</volume><issue>12</issue><fpage>1973</fpage><lpage>1984</lpage><pub-id pub-id-type="doi">10.1517/14712590802517970</pub-id><pub-id pub-id-type="other">2-s2.0-57649220640</pub-id><?supplied-pmid 18990084?><pub-id pub-id-type="pmid">18990084</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name></person-group><article-title>L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review</article-title><source><italic toggle="yes">Journal of Thoracic Disease</italic></source><year>2014</year><volume>6</volume><issue>10</issue><fpage>1513</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.3978/j.issn.2072-1439.2014.08.17</pub-id><pub-id pub-id-type="other">2-s2.0-84908542400</pub-id><?supplied-pmid 25364531?><pub-id pub-id-type="pmid">25364531</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larche</surname><given-names>M.</given-names></name></person-group><article-title>Peptide immunotherapy for allergic diseases</article-title><source><italic toggle="yes">Allergy</italic></source><year>2007</year><volume>62</volume><issue>3</issue><fpage>325</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2006.01309.x</pub-id><pub-id pub-id-type="other">2-s2.0-33846949713</pub-id><?supplied-pmid 17298351?><pub-id pub-id-type="pmid">17298351</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mocellin</surname><given-names>S.</given-names></name><name><surname>Pilati</surname><given-names>P.</given-names></name><name><surname>Nitti</surname><given-names>D.</given-names></name></person-group><article-title>Peptide-based anticancer vaccines: recent advances and future perspectives</article-title><source><italic toggle="yes">Current Medicinal Chemistry</italic></source><year>2009</year><volume>16</volume><issue>36</issue><fpage>4779</fpage><lpage>4796</lpage><pub-id pub-id-type="doi">10.2174/092986709789909648</pub-id><pub-id pub-id-type="other">2-s2.0-71949118684</pub-id><?supplied-pmid 19929787?><pub-id pub-id-type="pmid">19929787</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>D. S.</given-names></name></person-group><article-title>Peptide immunotherapy in vaccine development: from epitope to adjuvant</article-title><source><italic toggle="yes">Advances in Protein Chemistry and Structural Biology</italic></source><year>2015</year><volume>99</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/bs.apcsb.2015.03.001</pub-id><pub-id pub-id-type="other">2-s2.0-84946493914</pub-id><pub-id pub-id-type="pmid">26067814</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>T. P.</given-names></name><name><surname>Watson</surname><given-names>M. A.</given-names></name></person-group><article-title>Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer</article-title><source><italic toggle="yes">Annals of the New York Academy of Sciences</italic></source><year>2000</year><volume>923</volume><fpage>78</fpage><lpage>89</lpage><?supplied-pmid 11193781?><pub-id pub-id-type="pmid">11193781</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanem</surname><given-names>G.</given-names></name><name><surname>Fabrice</surname><given-names>J.</given-names></name></person-group><article-title>Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma</article-title><source><italic toggle="yes">Molecular Oncology</italic></source><year>2011</year><volume>5</volume><issue>2</issue><fpage>150</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2011.01.006</pub-id><pub-id pub-id-type="other">2-s2.0-79955465463</pub-id><?supplied-pmid 21324755?><pub-id pub-id-type="pmid">21324755</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minor</surname><given-names>D. R.</given-names></name></person-group><article-title>gp100 peptide vaccine in melanoma</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2011</year><volume>365</volume><issue>8</issue><fpage>p. 771</fpage><pub-id pub-id-type="doi">10.1056/NEJMc1107536</pub-id><pub-id pub-id-type="other">2-s2.0-80052162044</pub-id><?supplied-pmid 21864189?><pub-id pub-id-type="pmid">21864189</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz-Winnenthal</surname><given-names>F. H.</given-names></name><name><surname>Hohmann</surname><given-names>N.</given-names></name><name><surname>Niethammer</surname><given-names>A. G.</given-names></name><etal/></person-group><article-title>Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: a randomized, placebo-controlled, phase 1 trial</article-title><source><italic toggle="yes">OncoImmunology</italic></source><year>2015</year><volume>4</volume><issue>4, article e1001217</issue><pub-id pub-id-type="doi">10.1080/2162402X.2014.1001217</pub-id><pub-id pub-id-type="other">2-s2.0-84954342124</pub-id><?supplied-pmid 26137397?><pub-id pub-id-type="pmid">26137397</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurisicchio</surname><given-names>L.</given-names></name><name><surname>Ciliberto</surname><given-names>G.</given-names></name></person-group><article-title>Genetic cancer vaccines: current status and perspectives</article-title><source><italic toggle="yes">Expert Opinion on Biological Therapy</italic></source><year>2012</year><volume>12</volume><issue>8</issue><fpage>1043</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1517/14712598.2012.689279</pub-id><pub-id pub-id-type="other">2-s2.0-84863795689</pub-id><?supplied-pmid 22577875?><pub-id pub-id-type="pmid">22577875</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osada</surname><given-names>T.</given-names></name><name><surname>Morse</surname><given-names>M. A.</given-names></name><name><surname>Hobeika</surname><given-names>A.</given-names></name><name><surname>Lyerly</surname><given-names>H. K.</given-names></name></person-group><article-title>Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy</article-title><source><italic toggle="yes">Seminars in Oncology</italic></source><year>2012</year><volume>39</volume><issue>3</issue><fpage>305</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2012.02.013</pub-id><pub-id pub-id-type="other">2-s2.0-84861108589</pub-id><?supplied-pmid 22595053?><pub-id pub-id-type="pmid">22595053</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S. H.</given-names></name><name><surname>Danishmalik</surname><given-names>S. N.</given-names></name><name><surname>Sin</surname><given-names>J. I.</given-names></name></person-group><article-title>DNA vaccines, electroporation and their applications in cancer treatment</article-title><source><italic toggle="yes">Human Vaccines &#x00026; Immunotherapeutics</italic></source><year>2015</year><volume>11</volume><issue>8</issue><fpage>1889</fpage><lpage>1900</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1035502</pub-id><pub-id pub-id-type="other">2-s2.0-84938248921</pub-id><?supplied-pmid 25984993?><pub-id pub-id-type="pmid">25984993</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curcio</surname><given-names>C.</given-names></name><name><surname>Khan</surname><given-names>A. S.</given-names></name><name><surname>Amici</surname><given-names>A.</given-names></name><etal/></person-group><article-title>DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice</article-title><source><italic toggle="yes">Cancer Gene Therapy</italic></source><year>2008</year><volume>15</volume><issue>2</issue><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7701106</pub-id><pub-id pub-id-type="other">2-s2.0-38349056826</pub-id><?supplied-pmid 17992201?><pub-id pub-id-type="pmid">17992201</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolla</surname><given-names>S.</given-names></name><name><surname>Marchini</surname><given-names>C.</given-names></name><name><surname>Malinarich</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain</article-title><source><italic toggle="yes">Human Gene Therapy</italic></source><year>2008</year><volume>19</volume><issue>3</issue><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1089/hum.2006.196</pub-id><pub-id pub-id-type="other">2-s2.0-41149167241</pub-id><?supplied-pmid 18269312?><pub-id pub-id-type="pmid">18269312</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D. S.</given-names></name><name><surname>Mellman</surname><given-names>I.</given-names></name></person-group><article-title>Oncology meets immunology: the cancer-immunity cycle</article-title><source><italic toggle="yes">Immunity</italic></source><year>2013</year><volume>39</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.012</pub-id><pub-id pub-id-type="other">2-s2.0-84880706152</pub-id><?supplied-pmid 23890059?><pub-id pub-id-type="pmid">23890059</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castle</surname><given-names>J. C.</given-names></name><name><surname>Kreiter</surname><given-names>S.</given-names></name><name><surname>Diekmann</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Exploiting the mutanome for tumor vaccination</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2012</year><volume>72</volume><issue>5</issue><fpage>1081</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3722</pub-id><pub-id pub-id-type="other">2-s2.0-84857725402</pub-id><?supplied-pmid 22237626?><pub-id pub-id-type="pmid">22237626</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>M.</given-names></name><name><surname>Jhunjhunwala</surname><given-names>S.</given-names></name><name><surname>Phung</surname><given-names>Q. T.</given-names></name><etal/></person-group><article-title>Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing</article-title><source><italic toggle="yes">Nature</italic></source><year>2014</year><volume>515</volume><issue>7528</issue><fpage>572</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1038/nature14001</pub-id><pub-id pub-id-type="other">2-s2.0-84920956731</pub-id><?supplied-pmid 25428506?><pub-id pub-id-type="pmid">25428506</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carreno</surname><given-names>B. M.</given-names></name><name><surname>Magrini</surname><given-names>V.</given-names></name><name><surname>Becker-Hapak</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells</article-title><source><italic toggle="yes">Science</italic></source><year>2015</year><volume>348</volume><issue>6236</issue><fpage>803</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1126/science.aaa3828</pub-id><pub-id pub-id-type="other">2-s2.0-84928195112</pub-id><?supplied-pmid 25837513?><pub-id pub-id-type="pmid">25837513</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y. C.</given-names></name><name><surname>Yao</surname><given-names>X.</given-names></name><name><surname>Crystal</surname><given-names>J. S.</given-names></name><etal/></person-group><article-title>Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2014</year><volume>20</volume><issue>13</issue><fpage>3401</fpage><lpage>3410</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0433</pub-id><pub-id pub-id-type="other">2-s2.0-84903846565</pub-id><?supplied-pmid 24987109?><pub-id pub-id-type="pmid">24987109</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Schematic representation of different types of therapeutic cancer vaccines, which could be designed according to the forms of cells, proteins/peptides, and genes.</p></caption><graphic xlink:href="JIR2018-4325874.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The designing strategies and immunology of personalized neoantigen cancer vaccine. (I&#x02013;III) The tumor neoantigens of an individual are identified using the whole exome sequencing, and the personalized neoantigen cancer vaccine is introduced. (1) The APCs uptake the neoantigen peptides in the vaccination sites and then migrate to the lymph nodes. (2) The activated APCs present the neoantigens by MHC class I or MHC class II molecules to T cells. (3) The neoantigen-specific TCR recognizes the specific neoantigen presented by the MHC molecules of APCs. (4) The neoantigen-specific CD4<sup>+</sup> helper or CD8<sup>+</sup> cytotoxic T cells are activated and clonally expanded and then migrate to the tumor microenvironment. (5) The tumor cells are killed directly by neoantigen-specific CD8<sup>+</sup> cytotoxic T cells, leading to the release of more of tumor neoantigens. APC: antigen-presenting cell; MHC: major histocompatibility complex; TCR: T cell receptor.</p></caption><graphic xlink:href="JIR2018-4325874.002"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Categories of tumor antigens.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">Different antigen types, descriptions, and examples</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor-associated antigens (TAAs)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Low levels of expression on normal host cells</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Disproportionately expressed on tumor cells</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Often result from genetic amplification or posttranslational modifications</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Example: CD19 on B cell malignancies</td></tr><tr><td align="left" rowspan="1" colspan="1">Cancer germline antigens (CGAs)/cancer testis antigens (CTA)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Absent on the normal adult cells, except in reproductive tissues such as testes, fetal ovaries, and trophoblast</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Selectively expressed by various tumor types by epigenetic dysregulation</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Example: NY-ESO-1 in various tumors</td></tr><tr><td align="left" rowspan="1" colspan="1">Virus-associated antigens</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Arise in cancer cells from oncogenic viral proteins</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Viral oncoproteins integrate into host cell genome, causing cell transformation and tumorigenesis</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Carried by virally associated malignancies</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Example: HPV E6/E7 oncoproteins</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor-specific antigens (TSAs)/neoantigens</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Arise in cancer cells from nonsynonymous somatic mutations that result in the formation of new peptide sequences during tumorigenesis</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Completely absent from normal host cells</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Example: individual KRAS G12D somatic mutation</td></tr></tbody></table></table-wrap></floats-group></article>